Guggenheim Initiates Coverage On Zenas BioPharma with Buy Rating, Announces Price Target of $45
Portfolio Pulse from Benzinga Newsdesk
Guggenheim has initiated coverage on Zenas BioPharma with a Buy rating and set a price target of $45.
October 08, 2024 | 9:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim has initiated coverage on Zenas BioPharma with a Buy rating and a price target of $45, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $45 by a reputable analyst can lead to increased investor interest and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100